Designer type 2 diabetes drug comes with added benefits

Credit: CC0 Public Domain

A potential new treatment for type 2 diabetes has multiple, positive effects on health and metabolism in mice, reports a study in Nature. The new drug might have potential for treating a variety of disorders in addition to type 2 diabetes, such as muscle atrophy, although clinical trials in humans are needed.

An estimated 370 million people currently live with type 2 diabetes, and the figure is predicted to double by 2030. Although the disease can be managed with drugs, there is currently no therapy to halt or reverse its progression.

Mark Febbraio and colleagues combined features from two molecules—interleukin-6 (IL-6) and ciliary neurotrophic factor (CNTF)—which are known to improve and modify and , to create a new, designer molecule called IC7Fc. When tested in obese mice, the drug lowers blood glucose levels and prevents the build-up of lipids in the liver. The mice also eat less and lose weight while maintaining or increasing muscle mass.

On their own, the 'parent' drugs that IC7Fc is derived from have adverse effects that preclude their clinical development. However, IC7Fc displays no obvious side effects in mice and non-human primates. In light of these positive results, the authors now intend to progress to Phase I human clinical trials.

More information: Maria Findeisen et al. Treatment of type 2 diabetes with the designer cytokine IC7Fc, Nature (2019). DOI: 10.1038/s41586-019-1601-9
Journal information: Nature

Provided by Springer Nature
Citation: Designer type 2 diabetes drug comes with added benefits (2019, September 26) retrieved 8 December 2022 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Gene therapy reduces obesity and reverses type 2 diabetes in mice


Feedback to editors